Generics Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the company’s business strategy to maintain and grow its current level of success over the next five years. Ms. Itchon,…
Generics Romeo Carbonel, President & CEO of RBC-MDC Philippines, and Minerva Carbonel, COO of RBC-MDC, speak about how RBC-MDC was founded, its path to success since its founding, and whether or not it will be bought up by an MNC or passed down through the family in the future. As…
Generics David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and internationally. 2013 marks the thirtieth anniversary of Pharmascience. How does the company’s original business compare with its business today? Pharmascience was first established as…
Generics The Country President of AstraZeneca Philippines discusses the company’s new growth strategy, the need for affordable product pricing, and the growing knowledge initiatives the companies is producing in order to tackle the lack in qualified medical practitioners in the Philippines. When AstraZeneca’s global CEO Pascal Soriot took office late 2012,…
Generics Sanjay Singh, General Manager of Torrent in the Philippines, talks about the decision behind entering the Philippine market, the company’s strategy for increasing the influence of Indian pharmaceutical companies in the market, and how Torrent is contributing to the general awareness of patients with schizophrenia and psychosis, conditions that are…
CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…
Biogenerics The founder and general manager of Biotechnova considers the potential of Colombia for biotechnological innovation, and explains the current state of the biogeneric industry in Latin America. Please start by introducing yourself, and explaining how you came to found Biotechnova. My background is in microbiology and infections: since 2003, there…
R&D Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three of its products reimbursed in the last four years, and further highlights the affiliate’s successes and future growth outlook. How…
R&D Angelini Portugal’s Luigi Cianci offers his critique of the decline of Portugal’s economy and its effects on the industry, talking specifically about the company’s presence in Portugal and its export market—Angelini is one of a few multinationals that produces in conjunction with local facilities. What is your perception of the…
R&D Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and what the strategy is to stay afloat. You joined Celgene Portugal earlier this year; why were you chosen to take…
Array The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites the international life sciences com-munity to the island, the excitement was palpable. Foreign companies turned out in record numbers to…
See our Cookie Privacy Policy Here
